Oppenheimer set a $125.00 price objective on DexCom (NASDAQ:DXCM) in a research report sent to investors on Thursday, August 2nd, The Fly reports. The brokerage currently has a buy rating on the medical device company’s stock.
Other analysts also recently issued research reports about the company. BTIG Research reiterated a hold rating on shares of DexCom in a research note on Thursday, May 3rd. ValuEngine upgraded DexCom from a buy rating to a strong-buy rating in a research note on Wednesday, July 11th. Canaccord Genuity upped their target price on DexCom from $81.00 to $85.00 and gave the stock a buy rating in a research note on Thursday, May 3rd. BMO Capital Markets upped their target price on DexCom from $78.00 to $86.00 and gave the stock an outperformer rating in a research note on Thursday, May 3rd. Finally, JPMorgan Chase & Co. upgraded DexCom from a neutral rating to an overweight rating and upped their target price for the stock from $80.00 to $115.00 in a research note on Friday, June 8th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. DexCom has an average rating of Buy and a consensus price target of $102.19.
DexCom traded up $0.16, reaching $123.35, on Thursday, according to MarketBeat.com. 674,149 shares of the stock traded hands, compared to its average volume of 1,262,453. The firm has a market cap of $10.88 billion, a PE ratio of -212.67 and a beta of 0.05. The company has a quick ratio of 4.62, a current ratio of 4.89 and a debt-to-equity ratio of 0.69. DexCom has a 12 month low of $42.62 and a 12 month high of $127.31.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $242.50 million during the quarter, compared to analyst estimates of $205.81 million. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The business’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.16) EPS. research analysts expect that DexCom will post -0.48 earnings per share for the current year.
In other DexCom news, Director Nicholas Augustinos sold 12,300 shares of the stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $121.33, for a total transaction of $1,492,359.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $85.90, for a total value of $859,000.00. Following the transaction, the insider now directly owns 511,674 shares of the company’s stock, valued at approximately $43,952,796.60. The disclosure for this sale can be found here. Insiders have sold 187,400 shares of company stock valued at $17,965,063 in the last three months. Insiders own 1.80% of the company’s stock.
Several large investors have recently bought and sold shares of DXCM. UBS Group AG increased its position in shares of DexCom by 76.3% during the first quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock worth $1,181,000 after purchasing an additional 6,890 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of DexCom by 8.9% during the first quarter. JPMorgan Chase & Co. now owns 2,588,232 shares of the medical device company’s stock worth $191,943,000 after purchasing an additional 211,250 shares in the last quarter. Chicago Capital LLC increased its position in shares of DexCom by 52.9% during the second quarter. Chicago Capital LLC now owns 238,859 shares of the medical device company’s stock worth $22,687,000 after purchasing an additional 82,646 shares in the last quarter. Amalgamated Bank increased its position in shares of DexCom by 11.5% during the second quarter. Amalgamated Bank now owns 20,404 shares of the medical device company’s stock worth $1,938,000 after purchasing an additional 2,109 shares in the last quarter. Finally, Westwood Management Corp IL acquired a new stake in shares of DexCom during the second quarter worth about $2,084,000.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: Outstanding Shares
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.